ANI Pharmaceuticals ANIP Generics and Other total net revenues — Net Revenues

Similar metrics at other companies

VTRSGenerics — Net Sales

$1.18B+4.5%

AMRXOther dosage forms — Net revenue

$46.61M-17.4%

AMRXOther therapeutic classes — Net revenue

$13.95M+115%

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

TARSProduct sales, net — Total revenues

$145.39M+85.6%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

Questions, answered.

What is ANI Pharmaceuticals's generics and other total net revenues — net revenues?

ANI Pharmaceuticals (ANIP) reported generics and other total net revenues — net revenues of $109.22M in Q1 2026.

How has ANI Pharmaceuticals's generics and other total net revenues — net revenues changed year-over-year?

ANI Pharmaceuticals's generics and other total net revenues — net revenues increased by 6.0% year-over-year, from $103.04M to $109.22M.

What is the long-term trend for ANI Pharmaceuticals's generics and other total net revenues — net revenues?

Over 3 years (2022 to 2025), ANI Pharmaceuticals's generics and other total net revenues — net revenues has grown at a 19.3% compound annual growth rate (CAGR), from $235.24M to $399.41M.

What does generics and other total net revenues — net revenues mean?

This metric represents the total net revenue generated from the sale of generic prescription pharmaceuticals and related products within the company's portfolio. It reflects the market demand and pricing power for the company's diversified oral solid, liquid, and complex formulation offerings. Growth in this segment indicates successful product launches, effective lifecycle management, and the ability to capture market share in the competitive generic drug landscape.